Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.
Linda-Gail Bekker,Moupali Das,Quarraisha Abdool Karim,Khatija Ahmed,Joanne Batting,William Brumskine,Katherine Gill,Ishana Harkoo,Manjeetha Jaggernath,Godfrey Kigozi,Noah Kiwanuka,Philip Kotze,Limakatso Lebina,Cheryl E. Louw, Moelo Malahleha,Mmatsie Manentsa,Leila E. Mansoor,Dhayendre Moodley,Vimla Naicker,Logashvari Naidoo,Megeshinee Naidoo,Gonasagrie Nair, Nkosiphile Ndlovu,Thesla Palanee-Phillips,Ravindre Panchia, Saresha Pillay, Disebo Potloane,Pearl Selepe,Nishanta Singh,Yashna Singh,Elizabeth Spooner,Amy M. Ward, Zwelethu Zwane,Ramin Ebrahimi, Yang Zhao,Alexander Kintu, Chris Deaton,Christoph C. Carter,Jared M. Baeten,Flavia Matovu Kiweewa NEW ENGLAND JOURNAL OF MEDICINE（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper